Trial · NCT07906691
A Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy Participants
NCT07906691, Phase 1, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy Participants. Trials, record NCT07906691. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07906691
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy Participants
- NCT number
- NCT07906691
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 18 participants, estimated
- Lead sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Conditions
- Pancreatic Cancer
- Interventions
- HRS4642, Itraconazole Capsules
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The maximum plasma concentration (Cmax) | Post-dose at Day 1 to Day 44. | |
| Primary | Area under the blood drug concentration-time curve from time 0 corresponding to the last quantifiable concentration time (AUC0-t) | Post-dose at Day 1 to Day 44. | |
| Primary | Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC₀-∞) | Post-dose at Day 1 to Day 44. | |
| Secondary | Time to maximum plasma concentration (Tmax) | Post-dose at Day 1 to Day 44. | |
| Secondary | Terminal half-life (t1/2) | Post-dose at Day 1 to Day 44. | |
| Secondary | Terminal elimination rate constant (λz) | Post-dose at Day 1 to Day 44. | |
| Secondary | Volume of distribution at steady state (Vss) | Post-dose at Day 1 to Day 44. | |
| Secondary | Total systemic clearance / Total body clearance (CL) | Post-dose at Day 1 to Day 44. | |
| Secondary | Percentage of AUC extrapolated from the last measurable concentration to infinity (AUC_%Extrap) | Post-dose at Day 1 to Day 44. | |
| Secondary | The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) | Screening period up to Day 44. | Valuated by laboratory tests, electrocardiograms, vital signs, physical examinations, etc. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07906691
GET https://conductscience.org/api/trials/v1/NCT07906691/registered